DE602004028934D1 - Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung - Google Patents

Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung

Info

Publication number: DE602004028934D1
Authority: DE; Germany
Prior art keywords: benzoe4; dipyrimidin; therapeutic use; therapeutic
Prior art date: 2003-06-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE602004028934T

Other languages

English (en)

Inventor

Leena Hirvelae

Nina Johansson

Pasi Koskimies

Olli Taneli Pentikaeinen

Tommi Nyroenen

Tiina Annamaria Salminen

Mark Stuart Johnson

Pekka Lehtovuori

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Abbott Healthcare Products BV

Original Assignee

Abbott Healthcare Products BV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-10

Filing date

2004-06-09

Publication date

2010-10-14

2004-06-09 Application filed by Abbott Healthcare Products BV filed Critical Abbott Healthcare Products BV

2010-10-14 Publication of DE602004028934D1 publication Critical patent/DE602004028934D1/de

2024-06-10 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Addiction (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)
Joining Of Glass To Other Materials (AREA)

DE602004028934T 2003-06-10 2004-06-09 Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung Expired - Lifetime DE602004028934D1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US47704703P	2003-06-10	2003-06-10
PCT/EP2004/006230 WO2005032527A2 (en)	2003-06-10	2004-06-09	Benzo (4, 5) thieno (2, 3-d) pyrimidin-4-ones and their use in therapy

Publications (1)

Publication Number	Publication Date
DE602004028934D1 true DE602004028934D1 (de)	2010-10-14

Family

ID=34421462

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE602004028934T Expired - Lifetime DE602004028934D1 (de)	2003-06-10	2004-06-09	Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung

Country Status (24)

Country	Link
US (1)	US7465739B2 (de)
EP (1)	EP1635839B1 (de)
JP (1)	JP4605800B2 (de)
KR (1)	KR20060054189A (de)
CN (1)	CN1791412A (de)
AR (1)	AR044650A1 (de)
AT (1)	ATE479437T1 (de)
AU (1)	AU2004277311B8 (de)
BR (1)	BRPI0411295A (de)
CA (1)	CA2527617A1 (de)
DE (1)	DE602004028934D1 (de)
DK (1)	DK1635839T3 (de)
ES (2)	ES2352552T3 (de)
IL (1)	IL172316A0 (de)
MX (1)	MXPA05012745A (de)
NO (1)	NO20060123L (de)
PL (1)	PL1635839T3 (de)
PT (1)	PT1635839E (de)
RU (1)	RU2412190C2 (de)
SA (1)	SA04250159B1 (de)
SI (1)	SI1635839T1 (de)
TW (1)	TWI349551B (de)
WO (1)	WO2005032527A2 (de)
ZA (1)	ZA200508296B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7524853B2 (en)	2003-06-10	2009-04-28	Solvay Pharmaceuticals B.V.	Compounds and their use in therapy
JP2007536239A (ja) *	2004-05-06	2007-12-13	スミスクライン・ビーチャム・コーポレイション	カルシウム受容体アンタゴニスト化合物
WO2006044826A2 (en) *	2004-10-20	2006-04-27	Compass Pharmaceuticals Llc	Thiophens and their use as anti-tumor agents
DE602004021145D1 (de) *	2004-12-13	2009-06-25	Solvay Pharm Gmbh	NEUE SUBSTITUIERTE THIOPHENPYRIMIDINONDERIVATE ALS INHIBITOREN VON 17ß-HYDROXYSTEROIDDEHYDROGENASE
FR2904000A1 (fr) *	2006-07-19	2008-01-25	Galderma Res & Dev S N C Snc	Modulateurs de hsd17b7 dans le traitement de l'acne ou de l'hyperseborrhee
FR2904318B1 (fr) *	2006-07-27	2011-02-25	Scras	Derives de pyrimidinone et leur utilisation comme medicament
US8080540B2 (en)	2006-09-19	2011-12-20	Abbott Products Gmbh	Therapeutically active triazoles and their use
US8288367B2 (en)	2006-11-30	2012-10-16	Solvay Pharmaceuticals Gmbh	Substituted estratriene derivatives as 17BETA HSD inhibitors
DE102007015169A1 (de) *	2007-03-27	2008-10-02	Universität des Saarlandes Campus Saarbrücken	17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
WO2009001214A2 (en) *	2007-06-28	2008-12-31	Pfizer Products Inc.	Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
DE102007040243A1 (de)	2007-08-25	2009-02-26	Universität des Saarlandes	17Beta-Hydroxysteriod-Dehydrogenase Typ1 Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
JP2012513481A (ja)	2008-12-23	2012-06-14	プレジデントアンドフェロウズオブハーバードカレッジ	ネクロトーシスの小分子阻害剤
WO2012025638A1 (en)	2010-08-27	2012-03-01	Universität des Saarlandes	Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors
WO2012119605A1 (en) *	2011-03-10	2012-09-13	Akar Yahya Ahmed Abdellhafeez Salem	New disperse dye with potent anticancer activity
TW201520219A (zh) *	2013-03-12	2015-06-01	Lilly Co Eli	咪唑並吡啶化合物
US9725452B2 (en)	2013-03-15	2017-08-08	Presidents And Fellows Of Harvard College	Substituted indoles and pyrroles as RIP kinase inhibitors
TW201534612A (zh)	2013-06-25	2015-09-16	Forendo Pharma Ltd	治療用活性雌三烯噻唑衍生物
JP6456373B2 (ja)	2013-06-25	2019-01-23	フォレンドファーマリミテッド	１７β−ヒドロキシステロイドデヒドロゲナーゼタイプ１の阻害剤として治療活性のあるエストラトリエンチアゾール誘導体
AR096728A1 (es)	2013-06-25	2016-01-27	Forendo Pharma Ltd	Derivados de estratrieno-tiazol terapéuticamente activos
EP3089969A2 (de)	2014-01-03	2016-11-09	Elexopharm GmbH	Inhibitoren der 17-beta-hydroxysteroid-dehydrogenase typ 1 und typ 2
WO2015114663A1 (en)	2014-01-30	2015-08-06	Council Of Scientific & Industrial Research	Novel thieno [2,3-d]pyrimidin-4(3h)-one compounds with antimycobacterial properties
GB201419102D0 (en) *	2014-10-27	2014-12-10	Imp Innovations Ltd	Novel compounds
US10626140B2 (en)	2014-12-23	2020-04-21	Forendo Pharma Ltd	Prodrugs of 17β-HSD1-inhibitors
JP6523461B2 (ja)	2014-12-23	2019-06-05	フォレンドファーマリミテッド	１７β−ＨＳＤ１−阻害剤のプロドラッグ
CA3003930A1 (en) *	2015-11-04	2017-05-11	Simon Fraser University	Antibiotic compounds, pharmaceutical formulations thereof and methods and uses therefor
JP7064515B2 (ja)	2017-06-08	2022-05-10	フォレンドファーマリミテッド	１５β－［３－プロパンアミド］－置換エストラ－１，３，５（１０）－トリエン－１７－オン化合物および１７β－ヒドロキシステロイドデヒドロゲナ－ゼの阻害に使用するためのそれらの１７－オキシム
CN109503572B (zh) *	2017-09-15	2021-10-08	上海交通大学	一种合成吲哚喹啉类化合物的方法
EP3891167B1 (de)	2018-12-05	2024-11-13	Organon R&D Finland Oy	Estra-1,3,5 (10)-trien-verbindungen, kondensiert in position 16 (17) mit einem pyrazolring als inhibitoren von 17-hsd1
US20230416268A1 (en) *	2022-04-28	2023-12-28	Enanta Pharmaceuticals, Inc.	Pyrimidinone-containing 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS4742271B1 (de) *	1968-06-20	1972-10-25
US3775027A (en)	1971-10-01	1973-11-27	Gray Manuf Co Inc	Two-speed pump
JPS62132884A (ja)	1985-12-05	1987-06-16	Mitsubishi Chem Ind Ltd	２−ベンジルチエノ〔２，３−ｄ〕ピリミジン−４（３Ｈ）−オン誘導体
EP0364598A4 (en)	1988-03-02	1992-01-15	Yoshitomi Pharmaceutical Industries, Ltd.	3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof
US5597823A (en) *	1995-01-27	1997-01-28	Abbott Laboratories	Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
JP3783810B2 (ja)	1997-01-14	2006-06-07	第一製薬株式会社	新規ベンゾフラノン誘導体及びその製造方法
JPH10273467A (ja)	1997-01-29	1998-10-13	Snow Brand Milk Prod Co Ltd	新規テトラロン又はベンゾピラノン誘導体及びその製造方法
JP4166433B2 (ja)	1997-09-11	2008-10-15	第一製薬株式会社	ホルモン依存性疾患治療剤
MXPA00008868A (es)	1998-03-11	2003-04-25	Endorech Inc	Inhibidores de dihidrogenasa de 17 -hidroxiesteroide y metodos para su uso.
ES2281186T3 (es)	1998-08-07	2007-09-16	Novartis Vaccines And Diagnostics, Inc.	Pirazoles como moduladores de receptores de estrogenos.
GB9929302D0 (en)	1999-12-11	2000-02-02	Univ Cardiff	Benzyl tetralins compositions and uses thereof
WO2002026706A2 (en)	2000-09-29	2002-04-04	Bayer Pharmaceuticals Corporation	17-beta-hydroxysteroid dehydrogenase-ii inhibitors
WO2003017973A1 (en)	2001-08-31	2003-03-06	Pantarhei Bioscience B.V.	A method of treating benign gynaecological disorders and a drug delivery vehicle for use in such a method
CA2459311C (en)	2001-09-06	2010-08-03	Schering Corporation	17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US6750248B2 (en)	2001-11-09	2004-06-15	National University Of Singapore	Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof

2004
- 2004-06-07 US US10/861,907 patent/US7465739B2/en not_active Expired - Fee Related
- 2004-06-08 AR ARP040101983A patent/AR044650A1/es not_active Application Discontinuation
- 2004-06-08 TW TW093116411A patent/TWI349551B/zh not_active IP Right Cessation
- 2004-06-09 DK DK04803089.4T patent/DK1635839T3/da active
- 2004-06-09 WO PCT/EP2004/006230 patent/WO2005032527A2/en active Search and Examination
- 2004-06-09 CA CA002527617A patent/CA2527617A1/en not_active Abandoned
- 2004-06-09 DE DE602004028934T patent/DE602004028934D1/de not_active Expired - Lifetime
- 2004-06-09 KR KR1020057022958A patent/KR20060054189A/ko active IP Right Grant
- 2004-06-09 EP EP04803089A patent/EP1635839B1/de not_active Expired - Lifetime
- 2004-06-09 BR BRPI0411295-4A patent/BRPI0411295A/pt not_active IP Right Cessation
- 2004-06-09 JP JP2006515869A patent/JP4605800B2/ja not_active Expired - Fee Related
- 2004-06-09 SI SI200431535T patent/SI1635839T1/sl unknown
- 2004-06-09 ZA ZA200508296A patent/ZA200508296B/xx unknown
- 2004-06-09 RU RU2006100033/04A patent/RU2412190C2/ru not_active IP Right Cessation
- 2004-06-09 MX MXPA05012745A patent/MXPA05012745A/es active IP Right Grant
- 2004-06-09 ES ES04803089T patent/ES2352552T3/es not_active Expired - Lifetime
- 2004-06-09 PT PT04803089T patent/PT1635839E/pt unknown
- 2004-06-09 AT AT04803089T patent/ATE479437T1/de active
- 2004-06-09 CN CNA200480013515XA patent/CN1791412A/zh active Pending
- 2004-06-09 PL PL04803089T patent/PL1635839T3/pl unknown
- 2004-06-09 AU AU2004277311A patent/AU2004277311B8/en not_active Ceased
- 2004-06-12 SA SA4250159A patent/SA04250159B1/ar unknown
- 2004-11-03 ES ES04805369T patent/ES2352554T3/es not_active Expired - Lifetime
2005
- 2005-12-01 IL IL172316A patent/IL172316A0/en unknown
2006
- 2006-01-09 NO NO20060123A patent/NO20060123L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
US7465739B2 (en)	2008-12-16
TWI349551B (en)	2011-10-01
AU2004277311B2 (en)	2010-04-29
JP4605800B2 (ja)	2011-01-05
CA2527617A1 (en)	2005-04-14
EP1635839B1 (de)	2010-09-01
ATE479437T1 (de)	2010-09-15
NO20060123L (no)	2006-03-09
US20050038053A1 (en)	2005-02-17
AU2004277311A1 (en)	2005-04-14
WO2005032527A2 (en)	2005-04-14
TW200509937A (en)	2005-03-16
ES2352554T3 (es)	2011-02-21
EP1635839A2 (de)	2006-03-22
AU2004277311B8 (en)	2010-05-27
SI1635839T1 (sl)	2010-12-31
JP2006527226A (ja)	2006-11-30
RU2412190C2 (ru)	2011-02-20
KR20060054189A (ko)	2006-05-22
WO2005032527B1 (en)	2005-09-22
DK1635839T3 (da)	2011-01-03
WO2005032527A3 (en)	2005-08-04
ZA200508296B (en)	2007-01-31
PT1635839E (pt)	2010-10-12
PL1635839T3 (pl)	2011-02-28
AR044650A1 (es)	2005-09-21
ES2352552T3 (es)	2011-02-21
CN1791412A (zh)	2006-06-21
IL172316A0 (en)	2011-08-01
BRPI0411295A (pt)	2006-08-01
MXPA05012745A (es)	2006-05-17
SA04250159B1 (ar)	2008-06-21
RU2006100033A (ru)	2007-07-20

Publication	Publication Date	Title
DE602004028934D1 (de)	2010-10-14	Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung
ATE424202T1 (de)	2009-03-15	Substituierte 2-thio-3,5-dicyano-4-phenyl-6- aminopyridine und ihre verwendung
DE50207849D1 (de)	2006-09-28	Substituierte 2-oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre verwendung
DE60314600D1 (de)	2007-08-09	O-cyclopropyl-carboxanilide und ihre verwendung als fungizide
NL1025404A1 (nl)	2004-08-09	Pyrazolo-triazine verbindingen en gebruik daarvan.
NO20053974D0 (no)	2005-08-25	Tienopyrimidinforbindelser og anvendelse derav.
DE602004016839D1 (de)	2008-11-13	Cannabinoid rezeptor-liganden und ihre verwendung
DK1474420T3 (da)	2012-05-21	Quinazolinforbindelser
EE05505B1 (et)	2012-02-15	Personaalne teraapiasektsioon
DE502005007106D1 (de)	2009-05-28	Substituierte phenylaminothiazole und ihre verwendung
DE602004010426D1 (de)	2008-01-10	Mikrobizide zusammensetzungen und ihre verwendung
DE60230608D1 (de)	2009-02-12	Tyra-gene und ihre verwendung
ATE384054T1 (de)	2008-02-15	Substituierte benzoxazinones und ihre verwendung
ATE502035T1 (de)	2011-04-15	2-amido-4-phenylthiazol-derivate, ihre herstellung und ihre therapeutische verwendung
DE60230162D1 (de)	2009-01-15	Polymerisate und ihre verwendung
ATE459608T1 (de)	2010-03-15	Oxopiperidinderivate, ihre herstellung und therapeutische verwendung
DE60321372D1 (de)	2008-07-10	3-phenylpyridoindolderivate, ihre herstellung und verwendung
ATE353083T1 (de)	2007-02-15	Naphthyridin-derivate und ihre verwendung als fungizide
DE60324586D1 (de)	2008-12-18	Substituierte pyridyloxyalkylamide und ihre verwendung als fungizide
NO20050689L (no)	2005-03-21	Terapeutisk anvendelse
DE50313185D1 (de)	2010-11-25	2-pyrrolidin-2-yl-ä1,3,4ü -oxadiazol-derivate und ihre verwendung als antidepressiva
ATE372342T1 (de)	2007-09-15	Substituierte aminoisoxazolinderivate und ihre verwendung als antidepressiva
IS7694A (is)	2005-02-11	Sterasamrunaefnasambönd, framleiðsla og notkun þeirra
DE502004010917D1 (de)	2010-04-29	Rstellung und verwendung
NO20053898D0 (no)	2005-08-19	Use and proceeding at footballshoes

Legal Events

Date	Code	Title	Description
2011-09-07	R082	Change of representative	Ref document number: 1635839 Country of ref document: EP Representative=s name: LUTZ WERNER BAURIEGEL, 30173 HANNOVER, DE
2011-10-06	R097	No opposition filed against granted patent, or epo opposition proceedings concluded without decision	Ref document number: 1635839 Country of ref document: EP Effective date: 20110606

Date

Code

Title

Description

2011-09-07

R082

Change of representative

Ref document number: 1635839

Country of ref document: EP

Representative=s name: LUTZ WERNER BAURIEGEL, 30173 HANNOVER, DE

2011-10-06

R097

No opposition filed against granted patent, or epo opposition proceedings concluded without decision